Study guide
1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps
Board Certified Pediatric Pharmacy Specialist BCPPS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure
1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation
2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles
2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development
3 Chapter 3: Neonatal Critical Care & Prematurity Complications
3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis
4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections
4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections
5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections
5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections
6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus
6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices
7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders
7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities
8 Chapter 8: Pediatric Cardiology & Hemodynamics
8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management
9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support
9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK
10 Chapter 10: Pediatric Neurology & Psychiatric Disorders
10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders
11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders
11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia
12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care
12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care
13 Chapter 13: Pediatric Medication Safety & Error Prevention
13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions
14 Chapter 14: Pediatric Compounding & Formulation Technology
14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities
15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support
15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation
16 Chapter 16: Pediatric Pain Management, Sedation & Delirium
16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies
17 Chapter 17: Biostatistics & Study Design in Pediatric Research
17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values
18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics
18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations
19 Chapter 19: Pediatric Education, Health Literacy & Communication
19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials
20 Chapter 20: Pediatric Immunizations & Public Health Advocacy
20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy
21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics
21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management
1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps
Key Takeaways Explain This Topic AI
The Mosteller formula, BSA in square meters equals the square root of height in centimeters times weight in kilograms divided by 3,600, is the standard body surface area calculation for pediatric chemotherapy because it is reproducible at the bedside and requires only two measurements.
Body surface area dosing is generally avoided in infants under 12 months or under 10 kg; oncology protocols convert to weight-based dosing by dividing the square-meter dose by 30, so a 1,200 mg/m2 dose becomes 40 mg/kg.
Ideal body weight in children aged 2 to 20 years is most defensibly calculated as the 50th percentile BMI-for-age multiplied by height in meters squared, and adjusted body weight equals ideal body weight plus 0.4 times the difference between total and ideal body weight.
In pediatric obesity, total body weight is used for vancomycin, cefazolin, most beta-lactams, succinylcholine, and enoxaparin; adjusted body weight with a 0.4 factor is used for aminoglycosides; and ideal or adjusted body weight is used for acyclovir, with therapeutic drug monitoring wherever available.
A weight-based pediatric dose must never exceed the maximum recommended adult dose, so every calculation in a child above roughly 40 kg requires an explicit cap check before verification.
Last updated: September 2026
1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps
Pediatric dosing is an act of scaling. The question is never simply "how much drug?" but "how much drug per unit of what ?" — per kilogram of total body weight, per kilogram of some adjusted weight, or per square meter of body surface area. Choosing the wrong size descriptor produces a dose that is numerically defensible and clinically wrong, and this failure mode is heavily represented on the BCPPS examination because it is heavily represented in real pediatric harm.
Three measurements are non-negotiable before verifying any pediatric order: a weight recorded in kilograms only , a recent weight (a dosing weight more than a few days old is invalid in a neonate and unreliable in a fluid-overloaded critically ill child), and a length or height whenever body surface area is involved.
Body Surface Area
BSA correlates better than weight with basal metabolic rate, cardiac output, glomerular filtration rate, and extracellular fluid volume — the physiologic quantities that govern the clearance of cytotoxic agents. That is why oncology, and a handful of other domains such as some immunosuppressants and antifungals, dose by square meter.
The Three Formulas
Formula Equation Where used
Mosteller (standard) BSA (m 2 ) = Height (cm) × Weight (kg) 3600 \text{BSA (m}^2) = \sqrt{\dfrac{\text{Height (cm)} \times \text{Weight (kg)}}{3600}} BSA (m 2 ) = 3600 Height (cm) × Weight (kg) The default in pediatric oncology; simple enough to reproduce at the bedside and to double-check independently
DuBois & DuBois BSA = 0.007184 × Ht(cm) 0.725 × Wt(kg) 0.425 \text{BSA} = 0.007184 \times \text{Ht(cm)}^{0.725} \times \text{Wt(kg)}^{0.425} BSA = 0.007184 × Ht(cm) 0.725 × Wt(kg) 0.425 Historical standard; derived in only nine subjects, one of them a child
Haycock BSA = 0.024265 × Ht(cm) 0.3964 × Wt(kg) 0.5378 \text{BSA} = 0.024265 \times \text{Ht(cm)}^{0.3964} \times \text{Wt(kg)}^{0.5378} BSA = 0.024265 × Ht(cm) 0.3964 × Wt(kg) 0.5378 Derived specifically in infants and children; sometimes preferred in neonatology
The formulas agree closely in school-age children and diverge most in neonates and in severe obesity. Do not mix formulas within a treatment course — the protocol that defined the dose also defined the formula.
Worked Calculation
A 7-year-old is 120 cm tall and weighs 25 kg. Vincristine is ordered at 1.5 mg/m². BSA = 120 × 25 3600 = 3000 3600 = 0.8333 = 0.91 m 2 \text{BSA} = \sqrt{\frac{120 \times 25}{3600}} = \sqrt{\frac{3000}{3600}} = \sqrt{0.8333} = 0.91\ \text{m}^2 BSA = 3600 120 × 25 = 3600 3000 = 0.8333 = 0.91 m 2 Dose = 1.5 mg/m 2 × 0.91 m 2 = 1.37 mg → 1.4 mg \text{Dose} = 1.5\ \text{mg/m}^2 \times 0.91\ \text{m}^2 = 1.37\ \text{mg} \rightarrow 1.4\ \text{mg} Dose = 1.5 mg/m 2 × 0.91 m 2 = 1.37 mg → 1.4 mg
The conventional 2 mg absolute cap on a single vincristine dose is not exceeded, so 1.4 mg is dispensed. Had the child been 160 cm and 60 kg, BSA would be 1.63 m² and the uncapped calculation 2.45 mg — which must be capped at 2 mg .
The Infant Exception and the "Rule of 30"
Body surface area rises disproportionately to weight in small infants, so square-meter dosing systematically overdoses them. Pediatric oncology protocols therefore convert to weight-based dosing for patients who are under 12 months of age or under 10 kg (some protocols use under 12 kg): Dose (mg/kg) = Dose (mg/m 2 ) 30 \text{Dose (mg/kg)} = \frac{\text{Dose (mg/m}^2)}{30} Dose (mg/kg) = 30 Dose (mg/m 2 )
Cyclophosphamide 1,200 mg/m² becomes 40 mg/kg . Applying the m² dose directly to a 5 kg infant would deliver roughly a 50% overdose of a drug with a narrow therapeutic index.
Warning
Vincristine is the paradigm high-alert pediatric oncology drug: fatal if administered intrathecally . Independent of any BSA arithmetic, vincristine must be dispensed in a minibag, never a syringe , and labeled "For intravenous use only — fatal if given by other routes."
Selecting the Dosing Weight CHOOSING A SIZE DESCRIPTOR
Is the patient a neonate (<= 28 days)?
|-- YES -> Use BIRTH WEIGHT for the first 7-14 days of life,
| then current weight once birth weight is regained.
| Never dose on a weight inflated by edema.
|
|-- NO -> Is BMI-for-age >= 95th percentile (obesity)?
|-- NO -> TOTAL BODY WEIGHT, with an adult max cap.
- |
- |-- YES -> Drug-specific descriptor (see table below),
with an adult max cap and TDM if available.
Calculating Ideal and Adjusted Body Weight in Children
Adult equations such as Devine (50 kg + 2.3 kg per inch over 5 feet for males) are invalid below about 5 feet in height and therefore unusable in most children. The defensible pediatric method uses the growth chart itself: IBW (kg) = ( 50th percentile BMI-for-age ) × [ Height (m) ] 2 \text{IBW (kg)} = \left(\text{50th percentile BMI-for-age}\right) \times \left[\text{Height (m)}\right]^2 IBW (kg) = ( 50th percentile BMI-for-age ) × [ Height (m) ] 2 AdjBW (kg) = IBW + 0.4 × ( TBW − IBW ) \text{AdjBW (kg)} = \text{IBW} + 0.4 \times \left(\text{TBW} - \text{IBW}\right) AdjBW (kg) = IBW + 0.4 × ( TBW − IBW )
Worked example. A 10-year-old boy is 1.40 m tall and weighs 60 kg. The 50th percentile BMI-for-age at 10 years is approximately 16.5 kg/m².
IBW = 16.5 × ( 1.40 ) 2 = 16.5 × 1.96 = 32.3 kg \text{IBW} = 16.5 \times (1.40)^2 = 16.5 \times 1.96 = 32.3\ \text{kg} IBW = 16.5 × ( 1.40 ) 2 = 16.5 × 1.96 = 32.3 kg
AdjBW = 32.3 + 0.4 ( 60 − 32.3 ) = 32.3 + 11.1 = 43.4 kg \text{AdjBW} = 32.3 + 0.4(60 - 32.3) = 32.3 + 11.1 = 43.4\ \text{kg} AdjBW = 32.3 + 0.4 ( 60 − 32.3 ) = 32.3 + 11.1 = 43.4 kg
Gentamicin at 7 mg/kg extended interval: 7 × 43.4 = 304 mg 7 \times 43.4 = 304\ \text{mg} 7 × 43.4 = 304 mg , not 7 × 60 = 420 mg 7 \times 60 = 420\ \text{mg} 7 × 60 = 420 mg .
Dosing that child's aminoglycoside on total body weight would deliver a 38% excess, because adipose tissue contributes almost nothing to the volume of distribution of a hydrophilic aminoglycoside.
Size Descriptor by Drug Class in Pediatric Obesity
Drug or class Descriptor Rationale and caveat
Vancomycin Total body weight Clearance scales with total body weight; obese children generally need fewer mg/kg. Dose to an AUC24/MIC of 400–600 and cap the total daily dose (commonly 4,500 mg/day with a 2 g single-dose cap at many centers).
Aminoglycosides Adjusted body weight, factor 0.4 Hydrophilic; adipose contributes minimally to V d V_d V d . Mandatory therapeutic drug monitoring.
Acyclovir (IV) Ideal or adjusted body weight Total body weight dosing produces excessive exposure and crystalline nephropathy; hydrate aggressively and monitor renal function.
Cefazolin, most beta-lactams Total body weight, capped at the adult maximum Time-dependent killing; underdosing risks failure more than overdosing risks toxicity.
Enoxaparin Total body weight Monitor anti-Xa; obese children often need less per kilogram than lean children.
Unfractionated heparin, warfarin Total body weight with early monitoring Obese children frequently require fewer units or milligrams per kilogram.
Succinylcholine Total body weight Extracellular-fluid distribution and plasma cholinesterase activity both track total body weight.
Antineoplastics Total body weight or full uncapped BSA Reducing chemotherapy doses in obese patients is associated with worse outcomes; do not cap BSA at 2.0 m² unless the protocol says so.
Propofol Lean body weight for induction, total body weight for maintenance infusion Beware propofol infusion syndrome with prolonged high-rate infusion in children.
Digoxin Ideal body weight Distributes to lean tissue and skeletal muscle, not fat.
The Maximum-Dose Cap Belongs to the Size Calculation
Weight-based arithmetic has no upper bound; children do. Once a child approaches adult size, the weight-based dose must be compared against the adult maximum and the lower value dispensed : Dose = min ( Weight or BSA × dosing parameter , Maximum adult dose ) \text{Dose} = \min\left(\text{Weight or BSA} \times \text{dosing parameter},\ \text{Maximum adult dose}\right) Dose = min ( Weight or BSA × dosing parameter , Maximum adult dose )
Drug-by-drug caps and the clinical consequences of exceeding them are tabulated in the high-alert medication section of the medication safety chapter. What belongs here is the ordering of operations: choose the size descriptor first, calculate second, cap third. Selecting the right descriptor does not exempt the result from the cap, and applying the cap does not excuse having used the wrong descriptor. An obese adolescent dosed on total body weight for an aminoglycoside and then capped at an adult maximum is still being dosed on the wrong denominator.
Important
The reverse error also exists. An adolescent weighing 80 kg who is prescribed an adult fixed dose of a drug that is normally weight-based — for instance a 1 g vancomycin dose rather than 15–20 mg/kg — may be substantially underdosed . The cap rule is a ceiling, not a substitute for the calculation.
Practice Pearls & BCPPS Exam Traps
Exam Trap 1: Height, not just weight, is required for BSA. An order for a square-meter dose without a documented current height cannot be verified; a stated BSA carried forward from a prior admission is a common source of silent chemotherapy error.
Exam Trap 2: "Rounding" a BSA-derived chemotherapy dose to a convenient vial size is prohibited unless the protocol specifies a rounding tolerance (typically within 5%).
Exam Trap 3: Do not use adult Devine or Robinson ideal-body-weight equations in a child under 152 cm; they return nonsensical or negative values. Use the 50th percentile BMI-for-age method.
Board Rule: Any pediatric order that generates a dose at or above the adult maximum must stop at the adult maximum and prompt a call to the prescriber — with the single documented exception of antineoplastic protocols that explicitly direct full uncapped BSA dosing in obesity.